EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ocugen's enterprise value is €285.45 Mil.
Ocugen's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €5.54 Mil. Therefore, Ocugen's EV-to-Revenue for today is 51.57.
The historical rank and industry rank for Ocugen's EV-to-Revenue or its related term are showing as below:
FRA:2H51'
s EV-to-Revenue Range Over the Past 10 Years
Min: -2575.71 Med: 5587.2 Max: 53935.34
Current: 50.63
During the past 12 years, the highest EV-to-Revenue of Ocugen was 53935.34. The lowest was -2575.71. And the median was 5587.20.
FRA:2H51's EV-to-Revenue is ranked worse than 79.05% of 1031
companies
in the Biotechnology industry
Industry Median: 7.91
vs FRA:2H51: 50.63
As of today (2024-05-01), Ocugen's stock price is €1.221.
Ocugen's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.02. Therefore, Ocugen's PS Ratio for today is 55.50.
Ocugen EV-to-Revenue Historical Data
The historical data trend for Ocugen's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ocugen's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocugen's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocugen's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ocugen's EV-to-Revenue falls into.
Ocugen's current Enterprise Value is €285.45 Mil.
Ocugen's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocugen's share price for today is €1.221.
Ocugen's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocugen EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Ocugen's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:2H51 has been successfully added to your 